Shire plc : Director/PDMR Shareholding Director/PDMR

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
73
Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding

July 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Notification of transactions by persons discharging managerial responsibilities

1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name Susan Kilsby
2. Reason for the notification
a) Position / status Chairman - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("ADSs")
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs, being the part of Ms. Kilsby's total fees that are paid in ADSs for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
$164.4008 162
e) Date of the transaction June 30, 2017
f) Place of the transaction XNAS / ARCX
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name William Burns
2. Reason for the notification
a) Position / status Senior Independent Director - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")  
Identification code ISIN: JE00B2QKY057
b) Nature of the transaction Acquisition of Ordinary Shares, being the part of Mr. Burns' total fees that are paid in Ordinary Shares for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
£42.5500 156
e) Date of the transaction June 30, 2017
f) Place of the transaction XLON / BATE
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name Dominic Blakemore
2. Reason for the notification
a) Position / status Non-Executive Director - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")  
Identification code ISIN: JE00B2QKY057
b) Nature of the transaction Acquisition of Ordinary Shares, being the part of  Mr. Blakemore's total fees that are paid in Ordinary Shares for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
£42.5500 152
e) Date of the transaction June 30, 2017
f) Place of the transaction XLON / BATE
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name Olivier Bohuon
2. Reason for the notification
a) Position / status Non-Executive Director - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")  
Identification code ISIN: JE00B2QKY057
b) Nature of the transaction Acquisition of Ordinary Shares, being the part of Mr. Bohuon's total fees that are paid in Ordinary Shares for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
£42.5500 136
e) Date of the transaction June 30, 2017
f) Place of the transaction XLON / BATE
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name Ian Clark
2. Reason for the notification
a) Position / status Non-Executive Director - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("ADSs")
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs, being the part of Mr. Clark's total fees that are paid in ADSs for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
$164.4008 42
e) Date of the transaction June 30, 2017
f) Place of the transaction XNAS / ARCX
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name Gail Fosler
2. Reason for the notification
a) Position / status Non-Executive Director - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("ADSs")
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs, being the part of Ms. Fosler's total fees that are paid in ADSs for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
$164.4008 44
e) Date of the transaction June 30, 2017
f) Place of the transaction XNAS / ARCX
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name Steven Gillis
2. Reason for the notification
a) Position / status Non-Executive Director - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("ADSs")  
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs, being the part of Dr. Gillis' total fees that are paid in ADSs for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
$164.4008 47
e) Date of the transaction June 30, 2017
f) Place of the transaction XNAS / ARCX
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name David Ginsburg
2. Reason for the notification
a) Position / status Non-Executive Director - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("ADSs")
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs, being the part of Dr. Ginsburg's total fees that are paid in ADSs for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
$164.4008 48
e) Date of the transaction June 30, 2017
f) Place of the transaction XNAS / ARCX
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name Sara Mathew
2. Reason for the notification
a) Position / status Non-Executive Director - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("ADSs")
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs, being the part of Ms. Mathew's total fees that are paid in ADSs for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
$164.4008 46
e) Date of the transaction June 30, 2017
f) Place of the transaction XNAS / ARCX
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name Anne Minto
2. Reason for the notification
a) Position / status Non-Executive Director - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")  
Identification code ISIN: JE00B2QKY057
b) Nature of the transaction Acquisition of Ordinary Shares, being the part of Ms. Minto's total fees that are paid in Ordinary Shares for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
£42.5500 153
e) Date of the transaction June 30, 2017
f) Place of the transaction XLON / BATE
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name Albert Stroucken
2. Reason for the notification
a) Position / status Non-Executive Director - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("ADSs")  
Identification code ISIN: US82481R1068
b) Nature of the transaction Acquisition of ADSs, being the part of Mr. Stroucken's total fees that are paid in ADSs for the period of service from April 1 to June 30, 2017.
c) Price(s) and volume(s) Price(s) Volume(s)
See appendix below
d) Aggregated information - Aggregated volume - Price Weighted average price Volume
$164.4008 48
e) Date of the transaction June 30, 2017
f) Place of the transaction XNAS / ARCX

Appendix: individual / aggregated transaction details for PDMRs

Shire plc American Depositary Shares
Place of the transaction Price(s) Volume(s)
ARCX $164.3900 100
XNAS $164.3900 100
XNAS $164.4100 37
XNAS $164.4100 200
     
Place of the transaction Weighted average price Aggregated volume
ARCX $164.3900 100
XNAS $164.4041 337
     
Total $164.4008 437
 
Shire plc Ordinary Shares of 5 pence each
Place of the transaction Price(s) Volume(s)
XLON £42.5500 117
XLON £42.5500 70
XLON £42.5500 58
XLON £42.5500 46
XLON £42.5500 49
XLON £42.5500 150
XLON £42.5500 11
BATE £42.5500 96
     
Place of the transaction Weighted average price Aggregated volume
XLON £42.5500 501
BATE £42.5500 96
     
Total £42.5500 597

Oliver Strawbridge Senior Assistant Company Secretary

For further information please contact:

Investor Relations    
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media    
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com   +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 655

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 83

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

VivoPower Innovates with XRP-Focused Treasury Strategy

Updated Category News Views 359

VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...

Continue Reading
Recognizing Excellence in Product Stewardship for 2024

Updated Category News Views 114

Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...

Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty

Updated Category News Views 163

Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...

Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair

Updated Category News Views 257

Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...

Continue Reading
William James Wartinbee III Executes Significant Sell Strategy

Updated Category News Views 62

William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...

Continue Reading